Benign Prostatic Hyperplasia (BPH) Devices Market Size, Share & Trends Analysis by Product Type, Procedure Type, End User, and Geography - Global Opportunity Analysis and Industry Forecast (2026-2036)

The global benign prostatic hyperplasia (BPH) devices market is estimated to be USD 1.45 billion in 2026. This market is expected to reach USD 3.25 billion by 2036, growing at a CAGR of 7.8% during the forecast period 2026–2036.

• The global BPH devices market is projected to reach USD 3.25 billion by 2036, growing at a CAGR of 7.8% during the forecast period 2026–2036.
• North America is expected to dominate the global market in 2026, driven by the high prevalence of BPH in the aging population and established reimbursement policies.
• Asia-Pacific is projected to witness the fastest growth, fueled by the rapidly aging population and modernization of urological care in emerging economies.
• By product type, the minimally invasive surgical therapies (MIST) segment is expected to hold the largest share in 2026, due to strong patient preference for rapid recovery and sexual function preservation.
• By procedure type, transurethral resection of the prostate (TURP) is expected to account for the largest share in 2026, remaining the gold standard for surgical management.
• By end user, the hospitals & specialty clinics segment is expected to hold the largest share in 2026, as the primary setting for advanced BPH surgical interventions.
• Key players operating in the global market include Boston Scientific Corporation, Teleflex Incorporated, Olympus Corporation, PROCEPT BioRobotics Corporation, and Coloplast A/S.

                                                                                                                 Click here to: Get Free Sample Pages of this Report 

The global benign prostatic hyperplasia (BPH) devices market is experiencing significant growth, driven by the rising prevalence of BPH among aging male populations and the increasing adoption of minimally invasive surgical therapies (MIST). Benign prostatic hyperplasia, characterized by the non-cancerous enlargement of the prostate gland, is one of the most common urological conditions affecting older men. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), BPH affects approximately 50% of men aged 51–60 years and up to 90% of men older than 80 years. The growing burden of lower urinary tract symptoms (LUTS), including urinary frequency, urgency, nocturia, and incomplete bladder emptying, is increasing demand for effective and durable treatment solutions.

Demographic trends continue to support long-term market expansion. According to the United Nations, the global population aged 65 years and above is projected to increase from 857 million in 2025 to more than 1.3 billion by 2050, significantly expanding the patient pool susceptible to BPH. As healthcare systems increasingly focus on improving quality of life and reducing hospitalization costs, demand is shifting toward procedures that offer shorter recovery times, reduced complication rates, and preservation of sexual function compared with traditional surgical approaches.

Technological innovation remains a key market driver. Minimally invasive therapies such as Prostatic Urethral Lift (PUL), water vapor thermal therapy, temporary implantable nitinol devices, and robotic-assisted waterjet ablation are gaining clinical acceptance due to their favorable safety profiles and ability to deliver personalized treatment based on prostate anatomy and patient preferences. The American Urological Association (AUA) and the European Association of Urology (EAU) have expanded guideline recommendations for several minimally invasive treatment options, reflecting growing clinical evidence supporting their efficacy and durability.

In addition, the increasing migration of BPH procedures to outpatient and ambulatory surgical center settings is accelerating device adoption. Advanced therapies are often associated with reduced catheterization time, shorter hospital stays, and lower healthcare resource utilization compared with conventional transurethral resection of the prostate (TURP). As long-term clinical data continue to accumulate and reimbursement coverage expands across major healthcare markets, the adoption of advanced BPH devices is expected to accelerate throughout the forecast period, supporting continued innovation and market growth.

The growth of the global BPH devices market is primarily driven by the demographic shift toward an older population and the rising demand for minimally invasive treatments that minimize surgical risks.

Rapid Expansion of the Global Geriatric Male Population and Incident BPH Cases

A major driver for the market is the rapid expansion of the global geriatric male population, which is directly correlated with the rising incidence of BPH. As life expectancy increases worldwide, the number of men reaching the age where BPH symptoms become clinically significant is growing substantially. This demographic trend creates a massive and expanding patient pool for BPH devices. The increasing burden of lower urinary tract symptoms on the quality of life of older men is driving a higher volume of diagnostic consultations and subsequent surgical interventions, particularly as awareness of available treatment options grows.

Strong Patient and Physician Preference for Minimally Invasive Surgical Therapies (MIST)

The market is significantly driven by the strong preference among both patients and urologists for minimally invasive surgical therapies over traditional invasive surgery. Patients are increasingly seeking treatments that offer shorter recovery times, lower risk of complications, and preservation of sexual function. MIST procedures, which can often be performed in outpatient settings or under local anesthesia, align perfectly with these preferences. Physicians are also adopting these technologies as they allow for efficient office-based procedures and high patient satisfaction. This shift toward less invasive interventions is a fundamental driver for the adoption of advanced BPH devices.

Despite their clinical benefits, the adoption of advanced BPH devices is hindered by high capital costs and the lack of consistent reimbursement across different healthcare systems.

High Capital Investment and Maintenance Costs for Advanced Robotic and Laser Systems

A major restraint for the market is the high capital investment required for advanced BPH treatment systems, particularly robotic-assisted waterjet ablation and high-power laser systems. These technologies often involve significant upfront costs for the equipment, as well as ongoing expenses for specialized disposables and maintenance. For smaller hospitals and clinics, particularly in emerging markets, these costs can be prohibitive. This financial barrier can limit the availability of the most advanced BPH treatments to larger, well-funded medical centers, impacting overall market penetration and patient access to the latest technologies.

Inconsistent Global Reimbursement Policies and Variable Payer Coverage for New Technologies

The global BPH devices market is impacted by inconsistent reimbursement policies and variable coverage for newer minimally invasive technologies. While some advanced procedures are well-reimbursed in major markets like the U.S., they may still lack established codes or adequate coverage in other regions. This reimbursement uncertainty can deter healthcare providers from investing in new technologies and can limit patient access to treatments that are not fully covered by insurance or national health plans. The time-consuming process of securing favorable reimbursement for emerging BPH devices remains a significant hurdle for manufacturers and a restraint on rapid market expansion.

Future growth opportunities in the BPH devices market are centered on the migration of procedures to office-based settings and the increasing integration of robotics in urological care.

Significant Migration of BPH Treatments to Office-Based and Outpatient Settings

There is a significant opportunity for market growth driven by the migration of BPH treatments from hospital operating rooms to office-based and outpatient settings. Technologies like PUL and water vapor thermal therapy are specifically designed for this transition, offering high efficacy with a lower resource requirement. This shift allows urologists to improve practice efficiency and reduces the overall cost of care for healthcare systems. Manufacturers that focus on developing devices optimized for office-based use and providing comprehensive support for practice implementation are well-positioned to capitalize on this growing trend.

Increasing Adoption of Robotic-Assisted Systems for Precise and Heat-Free Tissue Ablation

The increasing adoption of robotic-assisted systems for BPH treatment represents a major opportunity. Technologies that offer highly precise and heat-free tissue ablation, such as waterjet systems, are gaining traction as they provide consistent outcomes across different prostate sizes while minimizing side effects. As robotic surgery becomes more prevalent in urology, there is a growing appetite for robotic BPH solutions. Manufacturers that can integrate advanced imaging, robotics, and precise ablation technologies are likely to lead the next generation of BPH care, offering superior clinical value and differentiation in a competitive market.

Increasing Clinical Emphasis on the Preservation of Sexual and Ejaculatory Function

A prominent trend in 2026 is the increasing clinical emphasis on preserving sexual and ejaculatory function during BPH treatment. According to the American Urological Association (AUA), sexual dysfunction and ejaculatory disorders remain among the most significant concerns influencing treatment selection among men with LUTS/BPH. Traditional procedures such as TURP are associated with retrograde ejaculation rates exceeding 50–70%, whereas newer minimally invasive therapies including Prostatic Urethral Lift (PUL) and water vapor thermal therapy have demonstrated substantially lower rates of treatment-related sexual dysfunction in clinical studies. Reflecting this shift, both AUA and European Association of Urology (EAU) guidelines increasingly incorporate sexual function preservation as a key consideration in treatment decision-making. As a result, demand is growing for non-ablative and minimally invasive devices that deliver durable symptom relief while maintaining quality-of-life outcomes.

Integration of AI-Driven Surgical Planning and Real-Time Ultrasound Guidance

The market is also witnessing increasing adoption of AI-enabled surgical planning and real-time ultrasound-guided interventions, particularly in robotic-assisted BPH therapies. Advanced platforms such as robotic waterjet ablation utilize real-time transrectal ultrasound imaging and treatment planning software to map prostate anatomy and precisely target obstructive tissue. Clinical studies have shown that image-guided robotic procedures can achieve significant improvements in International Prostate Symptom Score (IPSS) while maintaining low rates of irreversible complications. This trend aligns with the broader digital transformation of surgery, as healthcare providers seek technologies that improve procedural precision, standardize outcomes, reduce operator variability, and support the growing migration of BPH procedures to outpatient and ambulatory settings.

Analysis by Product Type

Based on product type, the minimally invasive surgical therapies (MIST) segment is expected to hold the largest share of the global BPH devices market in 2026. This leadership is substantiated by the strong patient preference for procedures that preserve sexual function and allow for rapid recovery. MIST procedures are increasingly performed in outpatient settings, driving their widespread adoption. However, the robotic-assisted waterjet ablation systems segment is projected to register the highest CAGR during the forecast period. The increasing clinical evidence supporting its high precision and heat-free tissue removal, combined with the broader trend toward robotic urology, is fueling the rapid growth of this advanced technology segment.

Analysis by Procedure Type

By procedure type, transurethral resection of the prostate (TURP) is expected to hold the largest share in 2026. TURP remains the gold standard for surgical BPH management due to its long-term efficacy and established clinical history. However, the prostatic urethral lift (PUL) segment is projected to grow at the fastest CAGR during the forecast period. The rising demand for office-based, non-ablative treatments that minimize the risk of sexual side effects is driving the rapid adoption of PUL, particularly among younger and more active BPH patients.

Analysis by End User

By end user, the hospitals & specialty clinics segment is expected to hold the largest share in 2026. Hospitals lead the market as they possess the comprehensive infrastructure and specialized robotic systems required for advanced BPH treatments. However, the ambulatory surgical centers (ASCs) segment is projected to register the highest CAGR during the forecast period. The ongoing shift toward minimally invasive and office-based procedures, combined with the lower cost structure and specialized focus of ASCs, is accelerating the migration of BPH treatments to these outpatient facilities.

Largest Share: North America

North America is expected to dominate the global BPH devices market in 2026, accounting for around 45% of total revenue. The region's leadership is driven by the high prevalence of BPH among its aging male population, widespread awareness of lower urinary tract symptoms (LUTS), advanced healthcare infrastructure, and strong adoption of minimally invasive surgical therapies. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), BPH affects approximately 50% of men aged 51–60 years and up to 90% of men over 80 years, supporting a large addressable patient population. The region has also been an early adopter of innovative therapies such as Prostatic Urethral Lift (PUL), water vapor thermal therapy, and robotic-assisted waterjet ablation, supported by favorable reimbursement frameworks and a well-developed ambulatory surgical center network. Key companies operating in the North American market include Boston Scientific Corporation, Teleflex Incorporated, PROCEPT BioRobotics Corporation, Medtronic plc, and Cook Medical LLC.

Fastest Growing: Asia-Pacific

The Asia-Pacific region is projected to witness the fastest growth in the global BPH devices market, with a CAGR of 8.5% during the forecast period. This rapid expansion is driven by the rapidly aging population in countries like China and Japan, increasing healthcare expenditures, and the modernization of urological care. The rising adoption of advanced laser and robotic systems in emerging economies is further accelerating market growth. Key companies operating in the Asia Pacific market are Olympus Corporation, Karl Storz SE & Co. KG, Richard Wolf GmbH, and Boston Scientific Corporation.

The global BPH devices market is characterized by intense competition among major medical device corporations and innovative specialized firms focusing on urological care. Competition is primarily focused on enhancing the precision of tissue ablation, reducing procedure times, and improving patient recovery profiles. Key players are investing heavily in long-term clinical trials to substantiate the efficacy and safety of their devices, particularly regarding the preservation of sexual function. Strategic developments often involve acquisitions of specialized technology firms and partnerships with urological research institutions to stay at the forefront of BPH care. Furthermore, there is a growing focus on providing comprehensive training and educational programs to urologists to support the successful implementation of new technologies. Manufacturers are also increasingly focusing on patient-directed awareness campaigns to educate men about the benefits of minimally invasive BPH treatments, which is critical for maintaining market leadership in this rapidly evolving and patient-centric field.

Boston Scientific Corporation, Teleflex Incorporated, PROCEPT BioRobotics Corporation, Olympus Corporation, Karl Storz SE & Co. KG, Richard Wolf GmbH, Lumenis Be Ltd., Dornier MedTech GmbH, Quanta System S.p.A., Cook Medical LLC, Medtronic plc, Coloplast A/S, Urotronic, Inc., Francis Medical, Zenflow, Inc., Allium Medical Solutions Ltd., JenaSurgical GmbH, OmniGuide Holdings, Inc., Intuitive Surgical, Inc., Stryker Corporation.